BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited has announced the issuance of 62 million shares to sophisticated investors at $0.10 each, under the Corporations Act without the need for a disclosure. The company confirms compliance with all necessary legal provisions and states there is no undisclosed ‘excluded information’ at the time of notice. BCAL Diagnostics is an innovative Australian firm focused on the early detection of breast cancer through non-invasive blood testing.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
